Oligonucleotide Therapeutics Society
Society News2021-08-27T10:57:04+00:00
26October, 2021

2021 Annual Meeting Highlights

October 26th, 2021|Categories: Perspectives on Current Science|

We enjoyed another excellent Annual Meeting this year! A more extensive meeting review from the organizing committee will be forthcoming, so be sure to watch for it. In the meantime, here is a broad overview highlighting a few of the many fascinating and intriguing presentations. Bob Letsinger, PhD – 100 Years of History Many of you probably enjoyed hearing ...

8October, 2021

Non-Profits Create Next-Generation Medicines that Treat Ultra-Rare Diseases

October 8th, 2021|Categories: Perspectives on Current Science|

Hundreds of millions of people worldwide are living with a rare disease. Most rare diseases do not currently have a cure. So, once diagnosed with a rare disease, most patients and their families are merely given strategies to manage the disease symptoms and try to minimize the impact on their lives. Sadly, those who receive a diagnosis are the ...

13September, 2021

Oligonucleotides Safely Cross the Blood-Brain Barrier to Knock Down Gene Expression

September 13th, 2021|Categories: Perspectives on Current Science|

Neurodegenerative diseases, brain tumors, and infectious diseases and inflammatory conditions that impact the brain wreak havoc on a person’s health and are notoriously difficult to treat. Oligonucleotide drugs could provide solutions to many pathological brain conditions if certain challenges could be overcome. Researchers at Tokyo Medical and Dental University, Takeda Pharmaceutical, and Ionis Pharmaceuticals may have found a solution. ...

25August, 2021

Ligand Conjugation – Expanding the Reach of Oligonucleotide Therapeutics

August 25th, 2021|Categories: Perspectives on Current Science|

Oligonucleotide therapies possess enormous potential as healing, life-changing, and cancer-curing drugs. However, there are many barriers to utilizing oligonucleotides to treat disease. Discovering or creating effective delivery methods for each target cell or tissue type solves many of these problems and there are multiple solutions that have proven to work in some capacity. In a previous article, we delved ...

9August, 2021

OTS President’s Paper Pick – August 2021

August 9th, 2021|Categories: Perspectives on Current Science, Presidents Pick|

By: Annemieke Aartsma-Rus, Ph.D. The paper information: CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis Julian D Gillmore, Ed Gane, Jorg Taube, Justin Kao, Marianna Fontana, Michael L Maitland, Jessica Seitzer, Daniel O’Connell, Kathryn R Walsh, Kristy Wood, Jonathan Phillips, Yuanxin Xu, Adam Amaral, Adam P Boyd, Jeffrey E Cehelsky, Mark D McKee, Andrew Schiermeier, Olivier Harari, Andrew Murphy, Christos ...

6August, 2021

Lipid Nanoparticles: Nanomedicine’s Triumph

August 6th, 2021|Categories: Perspectives on Current Science|

Oligonucleotide therapeutics have been making headlines this past year, between the groundbreaking new mRNA vaccines and the recent news of phenomenal interim results for Intellia’s investigational genome editing treatment for ATTR amyloidosis. Neither of these would have been possible without a lesser-known component – lipid nanoparticles. This delivery system has been decades in the making and, fortunately for humanity, ...

Go to Top